Literature DB >> 3293099

Regenerative effects of tetrachlorodecaoxide in BD IX rats after total-body gamma irradiation.

S Ivankovic1, S R Kempf.   

Abstract

Tetrachlorodecaoxide (TCDO) was tested for its effects in BD IX rats when combined with a single dose nearing LD50 of total-body irradiation (gamma rays, 60Co). In pilot tests we found that TCDO administrations prior to or immediately after irradiation led to a very high mortality rate (up to 90%), whereas the initiation of TCDO treatment on Day 2, 3, or 4 after irradiation lowered the death rate noticeably, with optimum results when TCDO application was started on Day 4. In our major experiment on 100 BD IX rats, it was demonstrated that the following treatment schedule considerably decreased the death rate (from 44 to 4%): 15.5 mumol TCDO/kg body wt/day on Days 4-6 after irradiation and 7.75 mumol/kg body wt/day on Days 7-11. The animals treated with TCDO showed only mild anemia in the peripheral blood, accompanied by reticulocytosis and low-grade leukocytopenia. Examination of the bone marrow on Day 12 after irradiation revealed X-ray-induced agranulocytosis in the animals that had received only physiological saline solution, whereas in the bone marrow of the animals treated with TCDO there was erythropoiesis as well as myelopoiesis. In addition, the degree of hair loss and depigmentation occurring about 1 month after irradiation was considerably reduced by TCDO. From these results it can be postulated that TCDO has two different effects: as an oxygen donator it causes radiosensitization in the tissue when given before or immediately after irradiation; as an agent stimulating phagocytes and tissue regeneration, it promotes regeneration very effectively when damage is already evident in the tissue.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3293099

Source DB:  PubMed          Journal:  Radiat Res        ISSN: 0033-7587            Impact factor:   2.841


  3 in total

1.  Randomized, double-blind, placebo-controlled trial of the immune modulator WF10 in patients with advanced AIDS.

Authors:  S P Raffanti; W Schaffner; C F Federspiel; R B Blackwell; O A Ching; F W Kühne
Journal:  Infection       Date:  1998 Jul-Aug       Impact factor: 3.553

2.  Salvage therapy with Sodium chlorosum (formerly DAC N-055) for cases of refractory lupoid cutaneous leishmaniasis: results from a compassionate use study with 0.09% Sodium chlorosum in amphiphilic basic cream.

Authors:  Sara Molkara; Elaheh Poursoltani; Kurt-Wilhelm Stahl; Masoud Maleki; Ali Khamesipour; Christian Bogdan; Maryam Salehi; Vahid Mashayekhi Goyonlo
Journal:  BMC Infect Dis       Date:  2019-11-28       Impact factor: 3.090

3.  Rapid healing of cutaneous leishmaniasis by high-frequency electrocauterization and hydrogel wound care with or without DAC N-055: a randomized controlled phase IIa trial in Kabul.

Authors:  Ahmad Fawad Jebran; Ulrike Schleicher; Reto Steiner; Pia Wentker; Farouq Mahfuz; Hans-Christian Stahl; Faquir Mohammad Amin; Christian Bogdan; Kurt-Wilhelm Stahl
Journal:  PLoS Negl Trop Dis       Date:  2014-02-13
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.